Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 416

Document Document Title
JP2008514688A
We have found anti-inflammatory activity in the ecteinascidin compounds. Such compounds have been widely described, and may have the following general formula (I): wherein: R5 is OH, alkoxy or alkanoyloxy; R6 is hydrogen, alkyl, alkenyl,...  
JP4066223B2  
JP2008505862A
The present invention relates to the use of ecteinascidin 743 in patients having certain levels of molecular markers who can predict the outcome of chemotherapy, in particular in patients having low levels of BRCA1 expression.  
JP2007530436A
This invention relates to benzopyran derivatives of formula (I) or (II), or pharmaceutically acceptable salts thereof wherein R1 and R2 are independently of each other hydrogen atom, C1-6alkyl group or C6-14aryl group, R3 is hydrogen ato...  
JP3973906B2
The present invention relates to a combination comprising component (a) being a compound of formula I, and component (b), being, at least one other drug useful in the treatment of arrhythmias and / or at least one other drug useful in th...  
JP2007204486A
To provide a novel intermediate compound useful as an intermediate of a compound particularly used for treating cardiac arrhythmia. The compound of formula XLII, a salt or a solvate thereof is useful as the intermediate for preparing the...  
JP2007513961A
The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form,...  
JP2007512397A
Under existence of the water which exceeds an antifoaming agent by a case and in which it exceeds an additive agent and about 10 % of the weight by a case under existence of a スチレンコ polymer dispersing agent, the present inventi...  
JP2006342182A
To provide a intermediate for producing oxabispidine compounds useful as antiarrhythmics and its production method.There is provided epoxy compounds shown by general formula (XLII), wherein R1a expresses an aryl sulfonyl group or the lik...  
JP2006523704A
The present invention is directed to compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X, n and the broken lines are as defined herein which are useful as modulators of chemokine receptor activity. In particular, thes...  
JPWO2006088191A
The present invention provides a you ジストミン derivative denoted by general formula (I) which shows antiviral activity to viruses, such as a hepatitis C virus, its salt, those hydrates, or solvent 和物.(R expresses among a formu...  
JP3787809B2
To provide a method for forming a 7 membered oxathiazepine ring in high yield by controlling a three-dimensional structure. This method for synthesizing an oxathiazepine ring is to synthesize a compound having an oxathiazepine ring expre...  
JP2002510633A5  
JP2006515350A
A compound of formula (I): wherein: represents benzo or pyrido, optionally fused in the 2-3, 3-4 or 4-5 position to a phenyl, (C4-C8)cycloalkyl or heterocyclic group, which may be optionally substituted, W represents X-Y or Y-X, wherein:...  
JP2006511551A
Aminocyanopyridine compounds are described which are capable of inhibiting mitogen activated protein kinase-activated protein kinase-2. Pharmaceutical compositions and kits are also described, which include an anminocyanopyridine MK-2 in...  
JP2006507255A
The present invention provides compounds and methods for treatment of viral diseases and cancer.  
JPWO2004039809A1
The inside of the general formula (I):[type whose present invention is a quinoxalinone derivative, and X, It is NH, S, etc., Y is O etc., and they are;B1, B-2, ..., Bn*1, and Bn (being here n). It is 4, 5, or 6.;B'1, B'2, ..., B'n*1, and...  
JP2006502238A
A method for manufacturing hydrogen sulphate (alpha S) of the alpha-(2-chlorophenyl)-6,7dihydrothieno[3,2-c]pyridine-5(4H) -acetic acid methyl ester (clopidogrel hydrogen sulphate) of formula I, in crystalline Form I, wherein the compoun...  
JP2005336088A
To provide a new bioactive substance having activities for inhibiting MRSA and VRE.The thiazole-based compound is represented by formula A (wherein, R is a group represented by formula B or an amino group). The compound has the anti-MRSA...  
JP2005523275A
The present invention provides compounds of formula: wherein R a and R b together with the carbon to which they are attached form a group of formula: where each X 1 is independently selected from hydrogen or substituted or unsubstituted ...  
JP2005517227A
A crystalline composition comprising a crystal of the IL-6 receptor I chain is provided. Also provided are methods of using the crystal and related structural information to screen for and design compounds that interact with IL-6R, or va...  
JP2005514334A
A compound of Formula Ior a pharmaceutically acceptable salt thereof, or a tautomer thereof, wherein G1, G2, and B are as defined in the application, are selective inhibitors of MMP-13. The compounds are useful for treating diseases medi...  
JP2005514387A
Provided are new crystalline Forms III, IV, V and VI of clopidogrel hydrogensulfate and the amorphous form of clopidogrel hydrogensulfate, as well as their pharmaceutical compositions, and method of treatments with such compositions. Als...  
JP2005509650A
Improved dosing schedules for ecteinascidin 743 are given for treatment of cancer.  
JP2005508898A
The invention relates to novel substituted, annelated indole and heteroindole derivatives of general formula (I), to tautomers, stereoisomers, mixtures and pharmaceutically acceptable salts thereof and to the production and use thereof a...  
JP2005501093A
Derivatives of ecteinascidin 736 are provided.  
JP2004536132A
Derivatives of Et-743 or Et-770 or Et-729 are provided. The derivatives are of the general formula (Ia) wherein the substituent groups take various permitted meanings.  
JP2004533466A
The present invention relates to benzoxazepine derivative having the general formula I, wherein X represents CO or SO2; R1, R2, R3 and R4 are independently selected from H, (C1-4)alkyl, (C1-4)alkyloxy, (C1-4)alkyloxy(C1-4)alkyl, halogen,...  
JP2004256450A
To obtain a new thia/oxaporphyrin-based compound having optical or electric function.The thiaporphyrin-based compound, the dithiaporphyrin-based compound, the oxaporphyrin-based compound, the dioxaporphyrin-based compound and the oxathia...  
JP2004526676A
This invention is directed to macroheterocyclic compounds useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.  
JPWO2004039809A
General formula (I) whose present invention is a quinoxalinone derivative:X are NH, S, etc. among [type and Y is O etc. ;B1B2..., Bn*1And Bn(here, n is 4, 5, or 6.) -- they are CH, N, etc. independently else mutually --;B'1B'2..., B'n*1A...  
JP2004511448A
Compounds of general structural formula (I), and use of the compounds or salts or solvates thereof as therapeutic agents, are disclosed  
JP2003533532A
Antitumor compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from...  
JP2003533533A
(57) The necessity about an alternative synthetic pathway over a summary エクチナサイジン compound and a related compound exists. Probably such a synthetic pathway offers the more economical way to the anti-tumor agent known, and...  
JP2003530402A
This invention relates to compounds of the formula: ##STR00001## wherein: the substituent groups defined by R.sub.1, R.sub.2 are each independently selected of H, C(.dbd.O)R', C.sub.1 C.sub.18 alkyl, C.sub.2 C.sub.18 alkenyl, C.sub.2 C.s...  
JP2003221395A
To obtain an intermediate capable of efficiently synthesizing an ecteinascidin, and a compound which facilitates the search for an analogue of ecteinascidin.The intermediate for the total synthesis of the ecteinascidin is the one having ...  
JP2003155290A
To provide a new ecteinascidin compound which is the stable equivalent of ecteinascidin 743.The ecteinascidin 786 represented by the structural formula, the method for separating and purifying the ecteinascidin 786 from colony ascidian, ...  
JP2003512352A
The present invention relates to a combination comprising component (a) being a compound of formula I, and component (b), being, at least one other drug useful in the treatment of arrhythmias and / or at least one other drug useful in th...  
JP2003508535A
The present invention is directed to macrocyclic compounds which inhibit prenyl-protein transferase (FTase) and the prenylation of the oncogene protein Ras. The invention is further directed to chemothera-peutic compositions containing t...  
JP2003012953A
To provide a method capable of efficiently preparing an azomethine colorant without the necessity for heat.This method for preparing an azomethine colorant comprises exposing an azomethine colorant precursor represented by general formul...  
JP2002544231A
ET743 is used in the preparation of a medicament for the treatment of the human body for cancer.  
JP2002544231A5  
JP2002544280A
Methods are provided for preparing a compound with a fused ring structure of formula (XIV) which comprises one or more reactions starting from a 21-cyano compound of formula (XVI) where typically; R1 is an amidomethylene group or an acyl...  
JP2002363185A
To provide a method for forming a 7 membered oxathiazepine ring in high yield by controlling a three-dimensional structure. This method for synthesizing an oxathiazepine ring is to synthesize a compound having an oxathiazepine ring expre...  
JP2002363180A
To provide an eudistomin intermediate compound improved with the yield and stereospecific selectivity in the forming process of a 7-membered oxathiazepine skeleton, a method for producing the same intermediate, and a new eudistomin analo...  
JP2002520365A
Novel thiazolyl peptide antibiotic compounds, including nocathiacin I, II and III, are disclosed. Also, novel microorganism ATCC-202099 is disclosed.  
JP2002519376A
The present invention is directed to peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions contai...  
JP2002519427A
The present invention is directed to peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions contai...  
JP2002517502A
The current invention relates to compounds of Formula Ipharmaceutical compositions and methods of use as nitric oxide synthase inhibitors, wherein the substituents are defined in the application.  
JP2002517502A5  

Matches 301 - 350 out of 416